ArticleEBioMedicine2026
Cepheid 9-gene host mRNA expression across the spectrum of Mycobacterium tuberculosis infection and disease: insights across the lifespan.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundNovel diagnostic solutions using host-response-based gene signatures to differentiate between individuals infected with Mycobacterium tuberculosis presenting with active tuberculosis disease (ATB), individuals infected with the bacterium in the absence of active tuberculosis disease (TBI), and individuals with no evidence of ATB or TBI (no TB) have demonstrated limited utility. However, the impact of age-related immunological changes on diagnostic performance remains unclear.
methodsUsing blood samples collected from 119 'adolescent/young adults' aged 10-24 years, 259 'adults' aged 25-55 years, and 79 'older adults' aged 56 years and above we explored differences in expression of eight gene targets using a novel research-use-only Cepheid Xpert TB/LTBI assay. We plotted relative expression for each gene by age stratified by TB status, then constructed two composite classifiers using a subset of gene targets. These composite classifiers were compared using AUCs derived from logistic regression models fitted within each age stratum.
findingsExpression of IL2, IFNG, and MIG appeared to best differentiate individuals who were classified as TBI or ATB from no TB and were used to construct an 'exposure' classifier which yielded an AUC of 0.89 (95% CI 0.83-0.96) among adolescent/young adults, 0.82 (95% CI 0.76-0.87) among adults, and 0.71 (95% CI 0.58-0.84) among older adults. Similarly, expression of SLPI, VEGFA, PLAU, and GBP5 appeared to best differentiate between individuals who were classified as ATB from TBI or no TB. The corresponding composite 'disease' classifier yielded an AUC of 0.88 (95% CI 0.80-0.96) among adolescent/young adults, 0.74 (95% CI 0.66-0.82) among adults, and 0.56 (95% CI 0.40-0.73) among older adults.
interpretationThis study demonstrates the importance of considering age in the development and evaluation of host-response-based diagnostics for ATB and TBI and suggests that host-response-based diagnostics may prove most useful in differentiation of ATB, TBI, and no TB among adolescent/young adults. FUNDINGS: This study was supported by the US Department of Defence (award number W81XWH-18-1-0253) and National Institutes of Health (award number R01AI137681). Salary support was received from the National Institutes of Health (training grant number T32AI007384).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.